CellVax News

top of page

CellVax Therapeutics

Sep 25, 2025

CellVax has an article published in the Network of the National Library of Medicine (NNLM)

CellVax Therapeutics

Jul 31, 2025

Cellipont Bioservices and CellVax Therapeutics Expand Partnership to Advance cGMP Manufacturing of Personalized Immunotherapy FK-GI101 for GI Cancers

CellVax Therapeutics

Feb 18, 2025

Theragent and CellVax Therapeutics Announce First Manufacturing Batch in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy

CellVax Therapeutics

Feb 18, 2025

CellVax is featured in the newspaper "Folha de São Paulo", Brazil.

CellVax Therapeutics

Feb 18, 2025

Fernando Kreutz in an interview with Jornal Da Gazeta, in Brazil

CellVax Therapeutics

Feb 18, 2025

We discovered a new way to modify this cell

CellVax Therapeutics

Feb 18, 2025

Prostate cancer vaccine developed in Brazil could revolutionize the treatment of the disease.

CellVax Therapeutics

Feb 18, 2025

CellVax is a featured subject on the "Fala Brasil" program on the Brazilian TV channel Record News.

CellVax Therapeutics

Feb 17, 2025

Brazilian vaccine against prostate cancer begins to be tested in the USA

CellVax Therapeutics

Feb 17, 2025

TV Record News interviews Fernando Kreutz

CellVax Therapeutics

Jan 30, 2025

If the results from 230 American patients are validated, the immunotherapy could be approved in about 18 months.

CellVax Therapeutics

Oct 31, 2024

CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy

CellVax Therapeutics

Oct 31, 2024

CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent

CellVax Therapeutics

Oct 31, 2024

Theragent to act as partner for CellVax’s Phase II cancer therapy

Developing the next generation of personalized immunotherapy

1951 NW 7TH Ave

3rd Floor | Suite 130
Miami | FL | 33136

© 2025 CellVax Therapeutics

Created by Gabriel Fabres

bottom of page